Inicia sesión Registrate Mi Biblioteca biblioteca abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.

Tratamiento farmacologico

374 ARTíCULOS , VIENDO DEL 346 AL 360

PUBMED

Therapeutics of Neurotransmitters in Alzheimer's Disease

Kandimalla R, Reddy PH.

J Alzheimers Dis. 2017;57(4):1049-1069. doi: 10.3233/JAD-161118.

0

0

0

PUBMED

The Role of Chromatography in Alzheimer's Disease Drug Discovery

Fiori J, De Simone A, Naldi M, Andrisano V.

Adv Chromatogr. 2017;53:75-107.

0

0

0

PUBMED

Molecular and Therapeutic Targets of Genistein in Alzheimer's Disease

Devi KP, Shanmuganathan B, Manayi A, Nabavi SF, Nabavi SM.

Mol Neurobiol. 2017 Nov;54(9):7028-7041. doi: 10.1007/s12035-016-0215-6. Epub 2016 Oct 28.

0

0

0

PUBMED

Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series

Devanand DP, Pelton GH, D'Antonio K, Strickler JG, Kreisl WC, Noble J, Marder K, Skomorowsky A, Huey ED.

Alzheimer Dis Assoc Disord. 2017 Jan-Mar;31(1):73-75. doi: 10.1097/WAD.0000000000000161.

0

0

0

PUBMED

Neurovascular Alterations in Alzheimer's Disease: Transporter Expression Profiles and CNS Drug Access

McInerney MP, Short JL, Nicolazzo JA.

AAPS J. 2017 Jul;19(4):940-956. doi: 10.1208/s12248-017-0077-5. Epub 2017 May 1.

0

0

0

PUBMED

Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease

Knez D, Sova M, Košak U, Gobec S.

Future Med Chem. 2017 May;9(8):811-832. doi: 10.4155/fmc-2017-0036. Epub 2017 May 15.

0

0

0

PUBMED

Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease

Li Q, Yang H, Chen Y, Sun H.

Eur J Med Chem. 2017 May 26;132:294-309. doi: 10.1016/j.ejmech.2017.03.062. Epub 2017 Mar 27.

0

0

0

PUBMED

Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer's disease

Wang YY, Zheng W, Ng CH, Ungvari GS, Wei W, Xiang YT.

Int J Geriatr Psychiatry. 2017 Jan;32(1):50-57. doi: 10.1002/gps.4571. Epub 2016 Sep 19.

0

0

0

PUBMED

Potential Neuroprotective Effects of Adiponectin in Alzheimer's Disease

Ng RC, Chan KH.

Int J Mol Sci. 2017 Mar 9;18(3):592. doi: 10.3390/ijms18030592.

0

0

0

PUBMED

Epileptic activity in Alzheimer's disease: causes and clinical relevance

Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL.

Lancet Neurol. 2017 Apr;16(4):311-322. doi: 10.1016/S1474-4422(17)30044-3.

0

0

0

PUBMED

Estrogen and Alzheimer's disease: Still an attractive topic despite disappointment from early clinical results

Merlo S, Spampinato SF, Sortino MA.

Eur J Pharmacol. 2017 Dec 15;817:51-58. doi: 10.1016/j.ejphar.2017.05.059. Epub 2017 May 31.

0

0

0

PUBMED

Amyloid beta: structure, biology and structure-based therapeutic development

Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE.

Acta Pharmacol Sin. 2017 Sep;38(9):1205-1235. doi: 10.1038/aps.2017.28. Epub 2017 Jul 17.

0

0

0

PUBMED

Drug discovery, development and delivery in Alzheimer's disease

Brambilla D.

Pharm Res. 2017 Dec 29;35(1):3. doi: 10.1007/s11095-017-2329-6.

0

0

0

PUBMED

Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies

Shinohara M, Tachibana M, Kanekiyo T, Bu G.

J Lipid Res. 2017 Jul;58(7):1267-1281. doi: 10.1194/jlr.R075796. Epub 2017 Apr 4.

0

0

0

PUBMED

Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis

Orgeta V, Tabet N, Nilforooshan R, Howard R.

J Alzheimers Dis. 2017;58(3):725-733. doi: 10.3233/JAD-161247.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neuroacademy